// App-Quantinova.ai

2572 : Early phase I study of the PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG).

Researchers

Presenter

  • Hussein Abdul-Hassan Tawbi

Principal Investigators

  • Edward Chu

  • Yan Lin

  • Laura Pollice

  • Leonard Joseph Appleman

  • Shannon Puhalla

  • Ronald G. Stoller

  • James J. Lee

  • Percy Ivy

  • Jan H. Beumer

  • Michelle A. Rudek

  • Afshin Dowlati

  • Patricia Lo Russo

  • Daniel Mulkerin

  • Helen K. Chew

  • Brian Kiesel

Medical Centers

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

  • University of California, San Francisco, CA

  • University of Wisconsin Hosp and Clinics, Madison, WI

  • University of Pittsburgh Medical Center, Pittsburgh, PAUniversity of Pittsburgh Cancer Institute, Pittsburgh, PANational Cancer Institute, Bethesda, MD

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • UPMC Cancer Center, Pittsburgh, PA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

  • University of Pittsburgh Medical Center, Womens Cancer Program at Magee-Womens Hospital of UPMC, Pittsburgh, PA

  • Albert Einstein Cancer Ctr/Montefiore, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Solid malignancies

  • Renal insufficiency

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

Drug/Treatment

  • Carboplatin

  • Paclitaxel

  • Veliparib

Outcome

  • Positive

Study Design

  • fixed dose

Phase

  • I

Study Id's

  • NCT01366144

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved